FDA removes hold on three CARsgen CAR-T trials; Ono passes on itolizumab
Plus, news about Kymera Therapeutics, Nanoscope, Eupraxia, Alpha Cognition and EyePoint:
FDA’s decision on CARsgen’s CAR-T therapies: The FDA on Thursday
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
